Literature DB >> 19857102

Calpain inhibitor SNJ-1945 attenuates events prior to angiogenesis in cultured human retinal endothelial cells.

Hong Ma1, Ayumi Tochigi, Thomas R Shearer, Mitsuyoshi Azuma.   

Abstract

PURPOSE: Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis and microvascular permeability. VEGF-induced cytoskeletal reorganization plays a crucial role in angiogenesis. Cytoskeletal organization in endothelial cells is regulated by calpain proteases (EC 3.4.22.17). Calpains are a family of 14 calcium-regulated, intracellular cysteine proteases, which modulate cellular functions by limited, specific proteolysis. Calpain 1 (mu-calpain) and calpain 2 (m-calpain) are the 2 major typical calpain isoforms and are responsible for most calpain activity in endothelial cells. The purpose of the present study was to determine if an orally available form of calpain inhibitor, SNJ-1945, prevented angiogenesis induced by VEGF in cultured retinal endothelial cells.
METHODS: Human retinal microvascular endothelial cells (HRMEC) were incubated with VEGF (60-100 ng/mL) for 24 h. Calcium uptake was measured with Fluo8. Total calpain activity was measured using fluorescent-labeled casein substrate, and separate activities for calpains 1 and 2 were assessed by casein zymography. Proteolysis of endogenous calpain substrate alpha-spectrin in situ was analyzed by immunoblotting. Angiogenesis in vitro was evaluated by measuring cell migration and tube formation into Matrigel.
RESULTS: Incubation of HRMEC with VEGF resulted in calcium uptake, increased activity of mainly calpain 2, and increased calpain proteolysis of alpha-spectrin. Treatment of endothelial cells with calpain inhibitor SNJ-1945 reversed VEGF-mediated tube formation and cell motility.
CONCLUSIONS: Inhibition of angiogenesis by specific calpain inhibitor in the presence of VEGF supported our hypothesis that calpains may be involved in VEGF-mediated angiogenesis in retinal endothelial cells. Therefore, manipulating calpain activity by calpain inhibitor SNJ-1945 might provide a promising therapy for management of pathological angiogenesis, such as that occurring in proliferative retinopathy and age-related macular degeneration with neovascularization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19857102      PMCID: PMC2958445          DOI: 10.1089/jop.2009.0030

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  30 in total

1.  How calpain is activated by calcium.

Authors:  Ahmad Khorchid; Mitsuhiko Ikura
Journal:  Nat Struct Biol       Date:  2002-04

2.  Calpain cleaves RhoA generating a dominant-negative form that inhibits integrin-induced actin filament assembly and cell spreading.

Authors:  Sucheta Kulkarni; Darrel E Goll; Joan E B Fox
Journal:  J Biol Chem       Date:  2002-04-18       Impact factor: 5.157

Review 3.  The role of calcium-activated protease calpain in experimental retinal pathology.

Authors:  M Azuma; T R Shearer
Journal:  Surv Ophthalmol       Date:  2008 Mar-Apr       Impact factor: 6.048

4.  Activation of m-calpain (calpain II) by epidermal growth factor is limited by protein kinase A phosphorylation of m-calpain.

Authors:  Hidenori Shiraha; Angela Glading; Jeffrey Chou; Zongchao Jia; Alan Wells
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

Review 5.  The role of vascular endothelial growth factor in angiogenesis.

Authors:  N Ferrara; H P Gerber
Journal:  Acta Haematol       Date:  2001       Impact factor: 2.195

Review 6.  Calpain: a role in cell transformation and migration.

Authors:  Neil O Carragher; Margaret C Frame
Journal:  Int J Biochem Cell Biol       Date:  2002-12       Impact factor: 5.085

Review 7.  The calpain system.

Authors:  Darrell E Goll; ValeryY F Thompson; Hongqi Li; Wei Wei; Jinyang Cong
Journal:  Physiol Rev       Date:  2003-07       Impact factor: 37.312

8.  Myoblast migration is regulated by calpain through its involvement in cell attachment and cytoskeletal organization.

Authors:  Stéphane Dedieu; Sylvie Poussard; Germain Mazères; Florence Grise; Elise Dargelos; Patrick Cottin; Jean-Jacques Brustis
Journal:  Exp Cell Res       Date:  2004-01-01       Impact factor: 3.905

9.  Longitudinal prevalence of major eye diseases.

Authors:  Paul P Lee; Zachary W Feldman; Jan Ostermann; Derek S Brown; Frank A Sloan
Journal:  Arch Ophthalmol       Date:  2003-09

Review 10.  Management of neovascular age-related macular degeneration.

Authors:  Ursula M Schmidt-Erfurth; Christian Pruente
Journal:  Prog Retin Eye Res       Date:  2007-03-27       Impact factor: 21.198

View more
  17 in total

1.  Calpain 1 and -2 play opposite roles in cord formation of lymphatic endothelial cells via eNOS regulation.

Authors:  Orawin Prangsaengtong; Kazutaka Senda; Yoshinori Doki; Jun Yeon Park; Michiko Jo; Hiroaki Sakurai; Naotoshi Shibahara; Ikuo Saiki; Keiichi Koizumi
Journal:  Hum Cell       Date:  2012-06       Impact factor: 4.174

2.  Calpain 10 homology modeling with CYGAK and increased lipophilicity leads to greater potency and efficacy in cells.

Authors:  Matthew A Smith; Campbell McInnes; Ryan M Whitaker; Christopher C Lindsey; Richard F Comer; Craig C Beeson; Rick G Schnellmann
Journal:  ACS Chem Biol       Date:  2012-05-31       Impact factor: 5.100

3.  CAPN5 genetic inactivation phenotype supports therapeutic inhibition trials.

Authors:  Katherine J Wert; Susanne F Koch; Gabriel Velez; Chun-Wei Hsu; MaryAnn Mahajan; Alexander G Bassuk; Stephen H Tsang; Vinit B Mahajan
Journal:  Hum Mutat       Date:  2019-08-26       Impact factor: 4.878

4.  CAPN5 mutation in hereditary uveitis: the R243L mutation increases calpain catalytic activity and triggers intraocular inflammation in a mouse model.

Authors:  Katherine J Wert; Alexander G Bassuk; Wen-Hsuan Wu; Lokesh Gakhar; Diana Coglan; MaryAnn Mahajan; Shu Wu; Jing Yang; Chyuan-Sheng Lin; Stephen H Tsang; Vinit B Mahajan
Journal:  Hum Mol Genet       Date:  2015-05-20       Impact factor: 6.150

5.  Protein Phosphotyrosine Phosphatase 1B (PTP1B) in Calpain-dependent Feedback Regulation of Vascular Endothelial Growth Factor Receptor (VEGFR2) in Endothelial Cells: IMPLICATIONS IN VEGF-DEPENDENT ANGIOGENESIS AND DIABETIC WOUND HEALING.

Authors:  Yixuan Zhang; Qiang Li; Ji Youn Youn; Hua Cai
Journal:  J Biol Chem       Date:  2016-11-21       Impact factor: 5.157

6.  Patient selection criteria for pilot studies on amelioration of non-neovascular age-related macular degeneration.

Authors:  Mitsuyoshi Azuma; Kelly Chung; Atsuko Fujii; Thomas R Shearer
Journal:  J Ocul Pharmacol Ther       Date:  2010-08       Impact factor: 2.671

7.  Calpain- and talin-dependent control of microvascular pericyte contractility and cellular stiffness.

Authors:  Maciej Kotecki; Adam S Zeiger; Krystyn J Van Vliet; Ira M Herman
Journal:  Microvasc Res       Date:  2010-08-12       Impact factor: 3.514

8.  VEGF Receptor-2-Linked PI3K/Calpain/SIRT1 Activation Mediates Retinal Arteriolar Dilations to VEGF and Shear Stress.

Authors:  Travis W Hein; Robert H Rosa; Yi Ren; Wenjuan Xu; Lih Kuo
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-08       Impact factor: 4.799

9.  SNJ-1945, a calpain inhibitor, protects SH-SY5Y cells against MPP(+) and rotenone.

Authors:  Varduhi H Knaryan; Supriti Samantaray; Sookyoung Park; Mitsuyoshi Azuma; Jun Inoue; Naren L Banik
Journal:  J Neurochem       Date:  2013-12-16       Impact factor: 5.372

Review 10.  Calpains, mitochondria, and apoptosis.

Authors:  Matthew A Smith; Rick G Schnellmann
Journal:  Cardiovasc Res       Date:  2012-05-11       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.